Daewoong Pharmaceutical Nabota, Export to Kuwait "Entering 5 Middle Eastern Countries"

[Financial News] Daewoong Pharmaceutical announced on the 25th that it has signed an export contract for the botulinum toxin 'Nabota' to Kuwait, further expanding its influence in the Middle Eastern market. This contract marks the fifth entry into the Middle East, and the fourth entry in the Gulf Cooperation Council (GCC) countries following UAE, Saudi Arabia, and Qatar. The GCC market is recognized as a premium market representing the Middle East due to its high interest in beauty and plastic surgery.
Kuwait has a high per capita income (about 32,000 dollars), well-established medical infrastructure, and active exchanges with other Gulf countries, making it strategically valuable with expected synergies. Daewoong Pharmaceutical plans to use Kuwait as a bridgehead to expand Nabota's entry into the entire Gulf region.
Daewoong Pharmaceutical is currently advancing its botulinum toxin products into the most Middle Eastern countries among domestic toxin brands, accelerating its penetration into the Middle Eastern market.
In particular, Daewoong Pharmaceutical is not only supplying products but also enhancing the procedural capabilities of Middle Eastern medical staff, ultimately increasing patient satisfaction with procedures and service quality, creating a 'WIN-WIN-WIN' model where the company, medical staff, and patients can all be satisfied.
Daewoong Pharmaceutical is conducting continuous academic activities on various topics, from its unique complex procedures to Nabota Lift, through conferences, webinars, and training programs, while also strengthening scientific evidence of Nabota's excellent quality and safety through clinical research cooperation with local medical staff.
Yoon Joon-soo, head of Daewoong Pharmaceutical's Nabota Business Division, said, “This entry into Kuwait will contribute to Nabota establishing itself as a representative brand in the Middle Eastern premium toxin market and strengthening market penetration,” adding, “Through differentiated academic activities and the dissemination of unique procedures based on clinical evidence and data, we will rapidly expand our presence throughout the Middle East.”

vrdw88@fnnews.com Kang Joong-mo Reporter